STVN
NYSE · Life Sciences Tools & Services
Stevanato Group Spa
$14.18
-0.16 (-1.12%)
Financial Highlights (FY 2026)
Revenue
1.15B
Net Income
122.44M
Gross Margin
28.7%
Profit Margin
10.7%
Rev Growth
+9.4%
D/E Ratio
0.31
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 28.7% | 28.7% | 51.2% | 51.2% |
| Operating Margin | 14.6% | 13.1% | 14.1% | 13.0% |
| Profit Margin | 10.7% | 10.1% | 9.2% | 10.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.15B | 1.05B | 2.66B | 2.46B |
| Gross Profit | 329.71M | 301.47M | 1.36B | 1.26B |
| Operating Income | 167.55M | 137.88M | 376.02M | 319.21M |
| Net Income | 122.44M | 100.76M | 245.63M | 251.38M |
| Gross Margin | 28.7% | 28.7% | 51.2% | 51.2% |
| Operating Margin | 14.6% | 13.1% | 14.1% | 13.0% |
| Profit Margin | 10.7% | 10.1% | 9.2% | 10.2% |
| Rev Growth | +9.4% | +9.4% | +4.0% | +22.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 508.21M | 508.21M | 579.44M | 635.38M |
| Total Equity | 1.66B | 1.66B | 1.94B | 2.00B |
| D/E Ratio | 0.31 | 0.31 | 0.30 | 0.32 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 180.08M | 156.42M | 513.68M | 453.60M |
| Free Cash Flow | — | — | 349.36M | 309.93M |